Going against AIDS group, FDA pledges quick review of Gilead drug to prevent HIV

A plan to use an approved HIV-fighting drug from Gilead Sciences Inc. as prevention to the AIDS virus will get priority review by the Food and Drug Administration, the agency said Monday.
The move means that the use of Truvada as a way to reduce HIV risk could be approved by June 15, rather than face a standard 10-month agency review.
If approved, Truvada would be the first drug for uninfected people to reduce the risk of acquiring HIV.
But Foster City-based Gilead (NASDAQ: GILD) faces a rough road on its way to winning approval of Truvada as a preventative treatment. At least one AIDS patient advocacy group, the AIDS Healthcare Foundation in Los Angeles, has opposed the plan.